KXV 01 TCR
Alternative Names: KXV 01 TCR Lentinvivo; KXV-01-TCRLatest Information Update: 24 Oct 2025
At a glance
- Originator TCRx Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 10 Oct 2025 The First Hospital of Jilin University plans a phase I trial for Solid tumours (Late stage disease, Metastatic disease, Second line therapy or greater) in China (Parenteral, Injection) in October 2025 (NCT07207681)
- 29 Sep 2025 Preclinical trials in Solid tumours in China (Parenteral)
- 29 Sep 2025 TCRx Therapeutics plans a phase-I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Injection), (NCT07196579)